Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 150 of 232 entries
View as:

Evaluation of the Effects of Omeprazole and Rifampin on the Pharmacokinetics of VX-548 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05635110 Org: User:
Start: 12/15/22 End: 06/08/23 Due: 06/08/24

Evaluation of Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty

Phase: N/A Priority: Normal
NCT ID: NCT05558410 Org: User:
Start: 10/10/22 End: 09/11/23 Due: 09/11/24

A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)

Phase: N/A Priority: Normal
NCT ID: NCT00420784 Org: User:
Start: 02/28/07 End: 04/30/09 Due: 04/30/10

Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702

Phase: N/A Priority: Normal
NCT ID: NCT00205478 Org: User:
Start: 06/30/05 End: 02/28/06 Due: 02/28/07

A Study of Suzetrigine (SUZ) Spray-dried Dispersion (SSD) in Healthy Adult Panelists

Phase: N/A Priority: Normal
NCT ID: NCT06834009 Org: User:
Start: 03/10/25 End: 04/24/25 Due: 04/24/26

Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT)

Phase: N/A Priority: Normal
NCT ID: NCT01614457 Org: User:
Start: 07/31/12 End: 10/31/13 Due: 10/31/14

A Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With Tezacaftor/Ivacaftor in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03486236 Org: User:
Start: 07/20/16 End: 09/14/16 Due: 09/14/17

An Open-Label, Phase 1 Study in Healthy Adult Subjects to Examine the Effects of Multiple-Dose Ciprofloxacin on Ivacaftor and VX-661 in Combination With Ivacaftor

Phase: N/A Priority: Normal
NCT ID: NCT02015507 Org: User:
Start: 01/31/14 End: 02/28/14 Due: 02/28/15

A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del

Phase: N/A Priority: Normal
NCT ID: NCT04105972 Org: User:
Start: 10/03/19 End: 07/24/20 Due: 07/24/21

Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

Phase: N/A Priority: Normal
NCT ID: NCT04058366 Org: User:
Start: 12/05/19 End: 12/16/22 Due: 12/16/23

A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT03029455 Org: User:
Start: 11/30/16 End: 08/31/17 Due: 08/31/18

A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

Phase: N/A Priority: Normal
NCT ID: NCT03447249 Org: User:
Start: 03/07/18 End: 02/05/19 Due: 02/05/20

Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/βC Genotype

Phase: N/A Priority: Normal
NCT ID: NCT05951205 Org: User:
Start: 04/30/24 End: 12/31/29 Due: 12/31/30

A Phase 1 Dose Escalation Study of Oral VX-708 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05347394 Org: User:
Start: 04/08/22 End: 04/14/23 Due: 04/14/24

Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation

Phase: N/A Priority: Normal
NCT ID: NCT01614470 Org: User:
Start: 07/31/12 End: 10/31/13 Due: 10/31/14

A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation

Phase: N/A Priority: Normal
NCT ID: NCT02742519 Org: User:
Start: 05/31/16 End: 08/31/17 Due: 08/31/18

A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)

Phase: N/A Priority: Normal
NCT ID: NCT03460990 Org: User:
Start: 05/01/18 End: 10/08/18 Due: 10/08/19

ELX/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients With at Least One F508del Mutation

Phase: N/A Priority: Normal
NCT ID: NCT04702360 Org: User:
Start: - End: - Due: -

Study of VX-770 in Subjects With Moderate Hepatic Impairment and in Matched Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01208285 Org: User:
Start: 09/30/10 End: 12/31/10 Due: 12/31/11

A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeries

Phase: N/A Priority: Normal
NCT ID: NCT06887972 Org: User:
Start: 03/21/25 End: 01/01/26 Due: 01/01/27

A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT07022119 Org: User:
Start: 06/12/25 End: 09/29/25 Due: 09/29/26

A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I

Phase: N/A Priority: Normal
NCT ID: NCT06926621 Org: User:
Start: 04/28/25 End: 07/24/28 Due: 07/24/29

A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Selected Surgeries

Phase: N/A Priority: Normal
NCT ID: NCT06887959 Org: User:
Start: 03/27/25 End: 01/15/26 Due: 01/15/27

A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT02951182 Org: User:
Start: 10/31/16 End: 08/31/17 Due: 08/31/18

A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)

Phase: N/A Priority: Normal
NCT ID: NCT01467479 Org: User:
Start: 12/31/11 End: 02/28/14 Due: 02/28/15